Wednesday, January 6, 2016
The Alliance for Clinical Research Excellence and Safety (ACRES), a Massachusetts-based nonprofit organization building a global system for clinical research, and ActivMed Practices & Research, a multi-specialty, free-standing research organization based in Massachusetts and New Hampshire, have announced a strategic alliance focused on enhancing quality and sustainability of clinical research sites.
Rochester, N.Y.-based iCardiac Technologies, a provider of cardiac safety assessments, has voiced support of the official release of a regulatory revision enacted by the International Council for Harmonization (ICH) that defines and enables an alternative path to the conduct of a Thorough QT (TQT) study in clinical drug development.
In the largest and most in-depth global survey of its kind, the Center for Information and Study on Clinical Research Participation (CISCRP) found the public has a high level of willingness to participate in clinical research, yet the industry lacks the ability to translate that support into clinical trial participation.
Do you hate to be late? Most people do, but CenterWatch surveys of investigative sites show the majority have delays. A root cause is increasing eligibility criteria (up 58% in the last decade). It is no wonder that sites say recruitment is the biggest cause of delay; with more criteria, fewer patients qualify.
CW Weekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trial space. Staff writer Ron Rosenberg interviewed Piet van der Graaf, Pharm.D., Ph.D., vice president of quantitative systems pharmacology at Certara and former director of XenologiQ, a QSP consultancy.